Femoral Nerve Block Compared to Exparel in Total Knee Replacement

Status unconfirmed · Phase 3

Conditions studied: Osteoarthritis, Pain

In brief

The main objective of the study is to determine if intrarticular injection with liposomal bupivicaine (Exparel) provides better postoperative pain relief and functional outcome following total knee replacement (TKR) than the current standard New England Baptist Hospital regimen of femoral nerve block combined with intraarticular injection of a standard bupivicaine solution.

Key facts

Study ID

NCT02473198

Run by

The New England Baptist Hospital

People needed

312

Starts

2014-01-01

Expected to finish

2017-02-01

Last updated by the study team

2016-03-17

Who can join

Age: 18 and older, up to 73. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients between the ages of 18 - 73 who are undergoing primary, unilateral, Total Knee Replacement at the New England Baptist Hospital in Boston, Massachusetts are eligible to participate.

You may not qualify if…

• Patients with Revision or Complex Total Knee Replacements and are under the age of 18, or over the age of 73 will be excluded.
• Patients with an ASA 4 level will be excluded.
• Patients with a Body Mass Index of less than 20, and over 40, will be excluded.
• Patients taking preoperative narcotics, patients with extreme sensitivity or allergy to narcotics or local anesthetics, and patients using opioid medications for at least 3 months leading up to surgery, will also be excluded.

Where it is running

• New England Baptist Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.